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ABSTRACT 
ObjectivesWe aim to characterise the future non-communicable disease (NCD) burden in 
Zimbabwe to identify future health system priorities. 
MethodsWe developed an individual-based multi-disease model for Zimbabwe, simulating 
births, deaths, infection with HIV and progression, and key NCD (asthma, chronic kidney 
disease (CKD), depression, diabetes, hypertension, stroke, breast, cervical, colorectal, liver, 
oesophageal, prostate and all other cancers). The model was parameterised using national and 
regional surveillance and epidemiological data. Demographic and NCD burden projections were 
generated for 2015 to 2035.  
ResultsThe model predicts that mean age of PLHIV will increase from 31to 45 years between 
2015 and 2035 (compared to 20 to 26in uninfected individuals). Consequently, the proportion 
suffering from ≥1 key NCD in 2035 will increaseby 26% in PLHIV and 6% in uninfected. Adult 
PLHIV will be twice as likely to suffer from ≥1 key NCD in 2035 compared to uninfected 
adults; with 15·2% of all key NCDsdiagnosed in adult PLHIV, whilecontributing only 5% of the 
Zimbabwean population. The most prevalent NCDswill be hypertension, CKD, depression, and 
cancers. This demographic and disease shift in PLHIV is mainly due to reductions in incidence 
and the success of ART scale-up leading to longer life-expectancy and,to a lesser extent, the 
cumulative exposure to HIV and ART. 
ConclusionsNCDs services will need to be expanded in Zimbabwe. They will need to be 
integrated into HIV care programmes, although the growing NCD burden amongst uninfected 
individualspresenting opportunities for additional services developed within HIV care to benefit 
HIV-negative persons.  
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INTRODUCTION 
Since 2000, an unprecedented global effort to increase access to HIV treatment has put 46% of 
persons living with HIV (PLHIV) on antiretroviral therapy (ART) globally.[1]Effective ART has 
extended life expectancy of PLHIV, and in the context of maturing HIV-treatment programs and 
a stabilising HIV epidemic, we are seeing an ageing population of PLHIV.[2–5] This introduces 
new challenges and pressures on ART programmes, as in addition to achieving 90:90:90 targets 
and moving to “test and treat” PLHIV will increasingly suffer from age-related non-
communicable diseases (NCDs).  
A recent model-based study provided the first insight into the shifting disease burden amongst 
ageing PLHIV, finding that by 2030 mean age of PLHIVin The Netherlands could increase from 
43·9 in 2010 to 56·6 years, with 84% suffering from at least one NCD and 54% taking at least 
one co-medication (in addition to HIV medication).[6] The study highlighted the clinical impact 
of the rising burden of NCDs, estimating that 40% of patients may experience complication due 
to contra-indication or drug-interactions with currently recommended ARTregimens by 2030.[6] 
While demographic changes in sub-Saharan African (SSA)countries with large HIV epidemics 
lags behind that of Western and Central Europe, similar shifts can be expected in the coming 
decades.[7,8] The associated evolving disease burdenwill exert significant pressure on care 
provision, particularly in settings where NCD management continues to remain specialized and 
access to services are limited. Theemerging NCD epidemicmay have important implications for 
ART programs and wider national health services.Substantial planning and strategic changes to 
service integration may be needed to sustain and build upon health gains achieved to date, 
particularlywhere health-care systems mainly provide episodic care for acute symptomatic 
conditions or services for maternal and infant health.[9,10]As concern about the management of 
NCDs amongst PLHIV grows, the infrastructure that has been built for the provision of ART and 
other HIV care services in vertical programs maybe leveraged and adapted to respond to the 
growing burden of NCDs, among both PLHIV and HIV-negative populations.[11] 
Zimbabwe has experienced a particularly high burden of HIV, but has seen recent declines in its 
HIV incidence.[12]Older adults compromise an increasingly large proportion of PLHIV in 
Zimbabwe.[8]A recent study from Zimbabwe has reported that the NCD burden amongst PLHIV 
is substantial, with 19·6% diagnosed with at least one NCD and 4·6% with multiple 
NCDs.[13]However, it is not known how this NCD burden will change over time and 
interactions with the evolving HIV epidemic and ART will drive changes. Detailed forecasts of 
the timing, scale and nature of the changing NCD burdenin the coming decadesare needed to 
help identify which servicesin Zimbabwe should be prioritized for rapid expansion and 
strengthening and for which populations. The aim of this study is to conduct model-based 
analyses of regional and national data to provide the first national predictions of changingage 
structure and NCD patternby HIV status in Zimbabwe, a hyper-endemic HIV setting in SSA.  
METHODS 
We constructed an individual-based multi-disease model for Zimbabwe, coded in C++. The main 
model features are summarized in Figure 1 and the full details can be foundin the supplement,  
http://links.lww.com/QAD/B218. Briefly, the model simulates the whole population of 
Zimbabwe, representingage, sex, birthsanddeaths, infection with 
HIVanddiseaseprogressionandthedevelopmentofseveralkey NCDs. 
Themodelusesdataandestimatesthatareavailablefortheperiodfrom1950 to 2015, with comparative 
checks of model output and data carried out for this period (supplement,  
http://links.lww.com/QAD/B218). The model was used to quantify the relative NCD burden in 
2015, and then run from 2015 to 2035 to provide detailed forecast of changing NCD burden by 
HIV status. The mechanisms of the model reply on “scheduling” events probabilistically at the 
start of a person’s life (e.g. their death) so that trends across the whole population recreate 
observed demographic, epidemiological and clinical trends (e.g. age-and-sex-specific mortality 
by calendar time). Events are determined probabilistically while accounting for a person’s 
characteristics (age, sex, pre-existing condition) and calendar time. For example, a male infant is 
more likely to die than a female infant and both are less likely to die before the age of one in 
2000 compared to 1950. As the model runs forward in time and new events occur these can 
influence future events or states. For example, a patient starting ART would have a reduced risk 
of a premature death (thus their date of death may be ‘re-scheduling for later in life or a patient 
who just developed hypertension may develop CKD later in life. 
DemographicprocessesinZimbabwewerebasedonestimatesfromUnitedNations’ (UN) 
DepartmentofEconomicandSocialAffairs.[14]Projections of demographic trends between 2015 
and 2035 assume a medium variant scenario.HIVincidencerateestimates, byage, sexandovertime 
(1970-2015)weretakenfromtheUNAIDSofficialestimates for Zimbabwe, 
whicharederivedthroughfittingamodeltoavailabledata 
frompopulationsinDemographicandHealthSurveys and routine HIV surveillance amongst 
pregnant women.[15]TheprocessofARTscale-up, withprogressivelyexpandingeligibilitycriteria, 
wasrepresentedandcalibratedtoUNAIDS estimates ofthenumbersofPLHIVinitiatingARTby CD4 
cell count inZimbabwe.[15]HIVdiseaseprogressionratesand mortality rates by CD4 cell count 
amongst PLHIV not on ART weretakenfromastudybyMangalet al.[16]Projections assume that 
HIV incidence remains stable at 2015 levels and that ART coverage increases steadily to reach a 
level of coverage consistent with 90:90:90 targets by 2035 (81% of PLHIV on ART by 2020). 
Additional results for sensitivity analyses around HIV incidence and ART coverage are 
presented in the supplement, http://links.lww.com/QAD/B218.  
The model simulates the development and diagnosis of severalkey NCDs: asthma, chronic 
kidney disease (CKD), depression, diabetes, hypertension, strokes and key cancers. The 
individual cancers, which were chosen based on the most prevalent non-AIDS defining cancersin 
Zimbabwe (as determined by 2012Globocan[17]), were: colorectal, liver, oesophageal, breast, 
cervical and prostate cancer as well as ‘other’ cancer, which comprise all other cancers. The 
choice of NCDs was based on key NCDs likely to play an important part in future clinicalcare 
and for which sufficient data wereavailable to make robust predictions.Parametersdefining NCD 
development and diagnosis were defined followinga literature review (Table 1), focusing on 
published studies recording age-specific prevalence or incidence ratesof NCD for Zimbabwe or 
neighbouring countries (with the assumption that neighbouring countries experience similar age-
specific prevalence patterns as Zimbabwe). Where studies presented prevalence estimates, age-
specific incidence rates were calculated, assuming age-specific incidence and prevalence 
estimates are constant over time. NCDs risks were based on age and on pre-existing NCDs. 
Treatment for NCDs was not explicitly simulated, implicitly assuming that whatever treatment is 
currently available would continue in the future. NCD-specific excess mortality risk was 
estimated by fitting the profile of cause-of-death in the model to 2013 Global Burden of Disease 
estimates for Zimbabwe.[18]Projections assume that patterns of underlying risk factors for NCD 
remain unchanged.  
The association of one NCDto increase the risk for development of another – for example for 
hypertension to increase the risk of having a stroke – was incorporated in the model following a 
literature review including studies from all regions (Table 2).[6] These links are illustrated by the 
red arrow in Figure 1. The increased risk for PLHIV to develop certain NCDs was incorporated 
into the modelthrough parameters based on a large study from The Netherlands that compares 
NCD risk amongst PLHIV and matched uninfected controls.[19]The study suggested that, 
amongst the NCDs included in our study, the prevalence of hypertension (45·4% vs 30·5%) and 
CKD (4·3% vs 2·1%) was significantly higher in PLHIV than age-matched uninfected controls, 
likely due to factors including immune suppression, systemic inflammation and innate immune 
activation.[19] 
Results 
Demographic Patterns 
TheUN demographic projections lead to a forecast of the population of Zimbabwe growingfrom 
15·5 million in 2015 to 23·5 million people by 2035. The model indicated that the population of 
PLHIV is expected to decrease in the same time period, from 1·2 million to 1·0 million, 
assuming levels of HIV-incidence remain constant. Although the age-structure of the whole 
population is projected to remain relatively stable (mean age 20 in 2015 and 26 in 2035) (Figure 
2A), the mean age of PLHIV in 2015 will rise rapidly,from 31 years in 2015to 45 years old by 
2035 (Figure 2B). This increase in mean age isdriven by the recent drop in HIV incidence and 
ART extending life-expectancy of PLHIV on ART.The model predicts that had ART not been 
introduced in Zimbabwe in 2004, mean age of PLHIV would be 34 by 2035, while if HIV 
incidence had remained at 1990s levels (highest incidence level), mean age would be 31.  
Patterns of Co-Morbidity in Zimbabwe 
PLHIV are more likely to be diagnosed with single or multiple morbidities in 2015 compared to 
uninfected persons (Figure 3A). An estimated 14% of HIV-negative persons are diagnosed with 
at least onekey NCD in 2015, compared to 33% of PLHIV, reflecting the differing age-structure 
in the two groups and the greater propensity of PLHIV to develop certain NCDs. However, even 
if PLHIV experienced no additional NCD risk relating to HIV and ART, 26% would suffer from 
one or more key NCDssimply due to their older average age. Modelled, age-standardized 
incidence rates per person suggest that the majority of these patterns will be driven by age (0.22 
and 0.23 in uninfected adults versus 0.2 and 0.24 in adult PLHIV in 2015 and 2035, 
respectively), rather than cumulative exposure to HIV and ART. 
This difference in multi-morbidity NCD prevalence by HIV status is forecast to become more 
pronounced over the coming 20 years. The proportion of PLHIV diagnosed with at least one key 
NCD is projected to increase from 33% in 2015 to 59% in 2035, and proportion diagnosed with 
two or more from 5% in 2015 to 16% in 2035 (Figure 3A). In the absence of additional NCD risk 
due to HIV-infection, fewer (36%) would be expected to be diagnosed with at least one NCD. 
This contrasts with projected key NCD prevalence among HIV-negative, with 21% diagnosed 
with at least one NCD in 2035. 
Amongst the NCDs evaluated by this model, the most prevalent NCDs between 2015 and 2035 
are hypertension, CKD, depression and ever having been diagnosed with (any) cancer. 
Prevalence in 2015 is higher amongst PLHIV compared to uninfected persons and will increase 
steeply by 2035 compared to uninfected persons (Figure 3C) (for example 25·0% of PLHIV are 
diagnosed with hypertension vs 5·6% of uninfected persons in 2015 and 47·5% vs. 7·7% in 
2035, 4·7% of PLHIV with CKD vs 1·2% of uninfected persons in 2015 and 8·0% vs. 1·5% in 
2035) (Figure 3C). The most prevalent cancers are cervical cancer (0·6% in 2015 vs. 0·8% in 
2035) and breast cancer (0·4% in 2015 vs. 0·8% in 2035 in all people). As hypertension is a risk 
factor for other NCDs, including serious cardiovascular outcomes (i.e. strokes) and CKD, this 
increase contributes to escalating numbers of persons with multiple co-morbidities.Age-
standardized incidence rates per person suggest that the majority of these patterns will be driven 
by age (e.g. 0.16 and 0.16 in uninfected adults versus 0.21 and 0.16 in adult PLHIV in 2015 and 
2035, respectively, for hypertension). 
While there is a predicted growth in prevalence of NCDs amongst PLHIV, most cases of NCDs 
will still be amongst HIV-negative persons (consistent with the fact that most people in the 
population are HIV-negative) and the total number of persons in Zimbabwe diagnosed with 
NCDs will nearly double or more in the coming 20 years (Figure 3B). The number of people 
diagnosed with hypertension will increase from 1·33 million (1·04 million (78%) HIV-negative 
and 0·29 million (22%) PLHIV) in 2015 to 3·06 million (2·57 million (84%) HIV-negative and 
0·49 million (16%) PLHIV). Other than hypertension, the NCDs which affect the greatest 
number of people are CKD, increasing from 0·27 million in 2015 (0·22 million (80%) HIV-
negative and 0·05 million (20%) PLHIV) to 0·59 million in 2035 (0·51 million (86%) HIV-
negative and 0·08 million (14%) PLHIV) and depression 0·18 million in 2015 (0·15 million 
(85%) HIV-negative and 0·03 million (15%) PLHIV) to 0·44 million in 2035 (0·38 million 
(88%) HIV-negative and 0·05 million (12%) PLHIV).  
 
Amongst people with at least two NCDs, a majority will suffer from hypertension with either 
CKD (21·2%), depression (16·6%), cancer (12·8%), diabetes (11·5%), asthma (10·0%) or stroke 
(4·7%) (Figure 3D), with trends similar by HIV status.Notable differences by HIV status include 
that while the major contributing multi-morbidity profiles amongst HIV-uninfected are 
composed of 2 NCDs, amongst PLHIV a large proportion consist of 3 NCDs. These include 
hypertension and CKD with either depression (2·1% in 2015 and 2·3% in 2035), diabetes (0·7% 
in 2015 and 1·6% in 2035), cancer (0·5% in 2015 and 1·4% in 2035), or hypertension with 
depression and cancer (0·2% in 2015 and 1·5% in 2035) (Figure 3D). 
DISCUSSION 
Without changes in underlying risk factors, the burden of key NCDs in Zimbabwe is set to 
increase steeply in the coming 20 years, particularly in PLHIV. This will have major 
implications for health care provisions, requiring substantial planning for additional services.The 
increase in NCD burden will be driven by population growth, and amongst PLHIV by the rapidly 
ageing populationof PLHIV (due to reductions in incidence and the success of ART scale-up) 
and,to a lesser extent, the cumulative exposure to HIV and ART. Our results suggest that by 
2035 adult PLHIV will be nearly twice as likely to suffer from at least one key NCD and three 
times more likely to suffer from multiple key NCDscompared to HIV-negative persons, and that 
15·2% of all key NCDs will be diagnosed in PLHIV, although they will contribute only 5·0% of 
the total Zimbabwean population. 
The changing patterns of disease burden will exert increasing pressure on already fragile health 
systems in the country at all levels of care.[20]Given resource constraints, the identification of 
cost-effective chronic disease service delivery models to manage the dual burden of HIV and 
NCDs will be critical to maintain the quality of health services in the country. In particular, there 
is a need to expand and strengthen the screening and treatment of hypertension, CKD, depression 
and cancers, as well as for prevention campaigns to be intensified.At the same time, the need to 
manage infectious diseases including tuberculosis, malaria and schistosomiasis (which also 
interact with HIV[21–23]), will remain in Zimbabwe for many years.[24]Existing vertical 
infectious disease programmes potentially offer a platform to expand NCD services, but may be 
over-burdened. Service integration has the potential to both reduce costs (for providers and 
patients) associated with multiple visits and improve the quality of care – if carefully designed 
and sufficiently resourced, as to not damage existing health gains. Further research is needed to 
identify the feasibility of integrating additional services – for PLHIV and uninfected persons -
into existing servicesand guide aspects such as monitoring and evaluation systems, targeted 
behavioural changes, demand generation for preventative services and linkage to care,[25]in a 
way that strengthens rather than depletes current human resource capacity in the health sector.  
Some important changes are already underway that may facilitate these efforts. HIV programs 
areshifting from vertical programs, focused on HIV diagnosis and treatment, to integrated care 
management, incorporating testing and treatment for other conditions, and exploring community 
based delivery.[26]Recent WHO guidelines have promoted integrated and differentiated care, 
which increasingly seeks to minimise the requirement of PLHIV that are stably virally 
suppressed to attend clinics.[27] As the PLHIV population ages, new protocolsshouldcarefully 
consider the extent to which patients with NCDs should have differential care, and balance the 
benefits of reduced treatment monitoring intensity against the benefits of risk group 
identification, screening and management of NCDs among PLHIV.[27] 
Our 2015 estimates arequalitativelysimilar to those reported in the 2015 cross-sectional study by 
Magodoroand colleagues.[13] This study found a large burden of single (19·6%) and multiple 
(4·6%) morbidity amongst their study population of PLHIV, and that hypertension (10%), 
diabetes (2·1%), asthma (4·3%) and cancers (1·8%) contributed a large burden of NCD. 
Differences observed between their results and ours (e.g. single morbidity 19·6% versus 28%, 
hypertension prevalence of 10% versus 25·0%, asthma prevalence of 4·3% versus 1·2%, 
diabetes prevalence of 2·1% versus 1·0% and cancer prevalence 1·8% versus 2·5% in their study 
compared to ours)may be in part due to the range of NCDs investigated, differences in NCD 
definitions, inclusion criteria for study participants and method used byMagodoro and 
colleagues, whoreviewing patients’ records for self-reported NCDs rather than clinical 
diagnosis.[13] 
This is the first model to forecast NCD burden in a low-middle income setting with high HIV 
burden, with a focus on the burden amongst PLHIV in particular and to show how this is driven 
by clinical interactions, the evolving HIV epidemiology and maturing ART program. Our results 
are likely to be relevant for other HIV hyper-endemic settings in Africa, which are undergoing 
rapid expansion of ART programs. Although further data collection and analysis on NCD trends 
in all countries is required, the results of this studyprovide an initial insight into the future NCD 
burden in a SSA country with a high HIV prevalence. 
Despite these strengths, the model is limited by sparse data availability for age-specific NCD 
incidence or prevalence estimates in Zimbabwe. This restricts the extent to which the output 
could be tested and validated and may translate into conservative estimate of future NCD burden 
to the extent to which specific NCDs are not included. A major assumption of this study is that 
age-specific prevalence estimates in Zimbabwe will be similar to those reported in neighbouring 
countries, including South Africa, and that the increased likelihood for an individual to develop 
an NCD based on pre-existing history of HIV or another NCD are translatable from high-income 
settings.The mechanisms driving increased NCD risk amongst PLHIV are complex and the 
relative contribution of various risk factors for NCDs in PLHIV is a topic of ongoing research. 
The model aims to capture the key factors relating to the HIV epidemic and attempts to 
incorporate the interdependence of NCDs and HIV in a manner consistent with best current 
understandings, but inevitably many layers of clinical interaction are not captured. For example, 
the model accounts for overall HIV-related risk for NCDs (e.g. related to inflammation of 
antiretroviral (ARV) use), but in the absence of robust projections on how ARVs usage may 
change over time, we do not include the impact of individual ARVs on NCDs.[29]Similarly, the 
model does not account for potential changes in health care access (other than 90:90:90 scale-up) 
or structural changes which may impact both NCD and HIV burden, e.g. integrating screening 
and treatment services for NCDs in HIV clinics may reduce NCD burden. Most research output 
come from high income settings,[29]and although we have used those insights here, the extent to 
which those interactions will pertain to the Zimbabwean populations remains unclear.We hope 
that these analyses will catalyse further data collection and reporting, and as more data on age-
specific NCD prevalence and risk factors for NCDs emerge from Zimbabwe, the model output 
can be updated.  
The model does not account for changes in survival rates with NCDs, and does not simulate all 
NCDs that can affect the population of Zimbabwe.Nor does the model simulate communicable 
diseases andhow increases in life expectancy could affect these or how reduction in fear of HVI 
transmission could increase risk behaviour and consequently sexually transmitted diseases. 
However, the model does model all cancers, including AIDS-defining cancers, which may result 
in an underestimation of the proportion of cancers in HIV-positive compared to HIV-negative 
people. Furthermore, NCD data is based on diagnosed cases and thus is likely to underestimate 
the true burden by excluding undiagnosed cases. These factors would tend to make the results a 
conservative estimate of the true NCD burden affecting Zimbabwe in the next 20 years. The 
model does not incorporate a transmission model, but rather simulates infection with HIV using 
incidence estimates[15]. Consequently, there is no dynamic feedback between processes in this 
model and those HIV incidence projections. 
Due to the lack of detailed data on lifestyle factors, such as smoking, alcohol consumption, diet 
and exercise, and lack of robust projections on how these factors may change in the coming 20 
years, the model assumes that the effect of lifestyle factors is uniform across the population and 
constant over time. If lifestyle-related risk factors are really restricted to a small proportion of the 
population in Zimbabwe, the model results may be over- or underestimatingthe number of people 
suffering from one or more NCD (overestimate in relation to smoking and alcohol consumption 
and underestimate in the case of healthy diet and exercise). As new data becomes available, the 
model results can be updated.  
The profile of the PLHIV in Zimbabwe, and elsewhere in Africa, is changing, presenting new 
challenges in terms of meeting their health care needs. Failing to adapt could lead to 
deteriorating outcomes for PLHIV and further strain fragile health systems. Existing vertical 
HIV programs may provide opportunity for new NCD screening services for PLHIV andan 
example for uninfected persons. A priority for health systems research in the coming years must 
be to establish how these many competing priorities can be managed effectively with the limited 
resources that are available to them. 
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Figure 1. Schematic of the multi-disease model for Zimbabwe. The model simulates 
demography (blue), HIV-infection (orange), and non-communicable diseases (green). The model 
accounts for demographic and medical risk factors for HIV-infection and for development of 
non-communicable diseases (red arrows to individual conditions and group of conditions). The 
model starts in 1950 and runs until 2035, making projections from 2015 onwards. Demographic 
and non-communicable disease patterns are simulated from 1950 and the HIV-epidemic from 
1975. From 2015, the model is used to forecast the timing and nature of non-communicable 
diseases in the general population and people living with HIV.  
 
 
 
 
 
  
Figure 2. Projected age distribution in Zimbabwe of the A. General population (includes people 
living with HIV and uninfected persons) and B. people living with HIV between 2015 and 2035.  
A.  
B.  
 
  
Figure 3.Projections of NCD burden. A.Proportion of people with 0, 1, 2, and 3 or more NCDs 
in 2015 and 2035 by HIV status.B. Number of people diagnosed with specific NCDs by HIV 
status in 2015 and 2035. C. Prevalence of specific NCDs by HIV status in 2015 and 2035. Solid 
colours refer to HIV-negative and shaded area to people living with HIV. D.Multi-disease profile 
by HIV-status amongst people with at least two NCDs in 2015 and 2035. Plain areas refer to 
2NCD combinations and dotted areas refers to 3 NCD combinations. Results shown as a cross-
section of the population with each square representing one patient.Abbreviations and 
definitions: HT – hypertension; stroke – refers to ever having had a stroke; CKD – chronic 
kidney disease; other cancers include all cancers other than breast, cervical, colorectal, liver, 
oesophageal, and prostate cancer;  
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Table 1. Age-specific incidence rates of non-communicable diseases diagnoses per 
100,000 person years.  
 Age Groups Setting Reference 
 19-49 50-59 >60   
Asthma* § 82·5 578·1 102·9 South Africa Negin et al, 2008 29 
Depression* § 204·8 475·3 62·9 South Africa Negin et al, 2008 29 
Diabetes* § 64·4 836·6 169·5 South Africa Negin et al, 2008 29 
Hypertension* 
§ 
1533·1 6005·9 1101·3 South Africa Negin et al, 2008 29 
Stroke* § 30·0 358·6 83·0 South Africa Negin et al, 2008 29 
 19-39 40-59 >60   
Kidney 
disease* ‡  
361·9 42·3 210·5 Tanzania Stanifer et al 201430 
 0-14 15-
39 
40-44 45-49 50-54 55-59 60-64 65-69 70-74 >75 
 
  
Breast cancer 
≠ 
0·0 5·0 42·6 59·6 80·2 98·5 108·8 116·0 119·9 118·0 Zimbabwe GloboCan17 
Cervical 
cancer ≠ 
0·0 8·3 71·2 105·8 136·3 166·0 220·5 263·3 299·1 328·1 Zimbabwe GloboCan17 
Colorectal 
cancer ≠ 
0·0 0·7 4·7 9·8 17·5 25·0 36·1 50·0 63·3 76·9 Zimbabwe GloboCan17 
Liver cancer ≠ 0·3 1·1 6·1 7·8 9·6 13·7 20·8 34·4 53·8 80·6 Zimbabwe GloboCan17 
Oesophagus 
cancer ≠ 
0·0 0·3 2·5 5·4 13·7 25·7 35·7 46·5 84·2 141·1 Zimbabwe GloboCan17 
Prostate 
cancer ≠ 
0·0 0·1 2·0 0·7 3·2 17·2 96·6 237·7 470·7 795·3 Zimbabwe GloboCan17 
Other cancers 
≠ 
10·9 43·5 132·6 152·1 170·0 189·6 282·7 442·2 530·9 678·4 Zimbabwe GloboCan17 
*Calculated from reported age-specific prevalence rates.  
‡Defined as estimated glomerular filtration rate ≤60ml/min/1·73m2 using the Modification of 
Diet in Renal Disease equation and/or persistent albuminuria.30 
≠ Defined using a number of data sources and methods, including regional incidence data and 
mortality data 17 
§ Defined using self-report of NCD diagnosis based on “ever having had”, validated against a 
diagnosis algorithm and symptoms questions.29 
 
Table 2. Association between risk of an individual developing a new disorder, in view of 
current disorder. Where patients had two or more NCDs thatcould affect the 
development of another NCD, we calculated parameters as the mean of the largest 
factorand the product of the factors. 
 
 
 Hazard 
ratio (95% 
CI) 
Source Setting 
Stroke given pre-existing diabetes vs stroke 
with no pre-existing diabetes. 
2·31  
(1·83-2·92) 
Worm and 
colleagues 2009 
31 
Europe, 
Argentina, 
Australia, USA 
Stroke given pre-existing hypertension vs 
stroke with no pre-existing hypertension 
1·26  
(0·98-1·62) 
Worm and 
colleagues 2009 
31 
Europe, 
Argentina, 
Australia, USA 
Hypertension given pre-existing diabetes vs 
hypertension with no pre-existing diabetes 
1·40  
(1·19-1·64) 
ATHENA data2 The Netherlands
Kidney disease given pre-existing diabetes 
vs kidney disease with no pre-existing 
diabetes 
1·50  
(1·05-2·15) 
Mocroft and 
colleagues 
201032 
Europe, 
Argentina and 
Israel 
Kidney disease given pre-existing 1·69  Mocroft and Europe, 
hypertension vs kidney disease with no pre-
existing hypertension 
(1·26-2·27)  colleagues 
201032 
Argentina and 
Israel 
 
 
